William Slayton, M.D.
Professor
About William Slayton
My patients and colleagues call me Dr. Bill, and I joined the division of pediatric hematology and oncology in 2002, with a focus on platelet disorders and leukemia. I received my bachelor’s degree in biology from Oberlin College and my medical degree from the University of Florida. I also completed a pediatric internship, pediatric residency and pediatric fellowship at UF.
I was inspired to go into medicine by my father, who was a pioneer in adult oncology. I always admired him for his work but could not imagine how he could work with such sick people. When I was in medical school and as a resident, I was always most comfortable working with patients with cancer, and I am sure this is because of my father’s influence. I am naturally a pediatrician as I love to work with children. I am now the chief of the division, and I also chair the Children’s Oncology Group clinical trial AALL0622, Improved Targeted Tyrosine Kinase Therapy for Ph+ Acute Lymphoblastic Leukemia.
As a pediatric oncologist, I have worked hard to improve the treatments for children with leukemia. I have been fortunate to have the opportunity to work on and then lead clinical trials using new targeted therapies for children with high-risk leukemia. My laboratory has interest in how normal and leukemic stem cell interact with the bone marrow microenvironment. My current projects are focused on developing better therapies for Ph+ acute lymphoblastic leukemia and infant leukemia.
My goal is to be a great teacher and lead my division and my department to provide the best care for our patients. My experiences with my own parents’ illnesses has instilled in me a fierce allegiance with my patients. I have assembled a team of like-minded providers who want to do the very best for our kids.
In my free time, I frequently volunteer at Camp Boggy Creek, sing in three a cappella groups and write limericks. I’ve also organized wilderness river trips for children who have completed their cancer treatment. I have three amazing children with my wife, Dr. Marci Slayton who is a pediatrician and in my free time I enjoy spending time gardening, bird-watching and cooking.
Accomplishments
Eugene F. Tubbs M.D., J.D. Award
1992
·
University of Florida
Hugh and Cornelia Carithers Awards
1992
·
University of Florida
Teaching Profile
Courses Taught
2020,2024
BMS6631 Hematology
2015,2017-2020
GMS6065 Fundamentals of Cancer Biology
2013-2018
MDT7400 Elect Top/Pediatrics
2018
MDC7400 Pediatric Clerkship
2018
MDC7401 Senior Pediatric Clk
2010-2013
MEL7937 Elect Top/Pediatrics
2021,2024
BMS6816 Cancer Bio Clin Oncol
Board Certifications
-
Pediatric Hematology/OncologyAmerican Board of Pediatrics
-
PediatricsAmerican Board of Pediatrics
Clinical Profile
Specialties
- Pediatrics
Subspecialties
- Pediatric Hematology-Oncology
Areas of Interest
- Bladder Cancer
- Bone marrow transplant
- Breast Cancer
- Cancer treatment information
- Colorectal cancer
- Esophageal cancer
- Gynecological cancer
- Leukemia
- Lung Cancer
- Lymphoma
- Melanoma of the eye
- Non-Hodgkin lymphoma
- Thrombocytopenia
Publications
Academic Articles
2025
A case of primary cutaneous marginal zone lymphoma in a 12‐year‐old with mast cell activating syndrome
Pediatric Blood & Cancer.
72(1)
[DOI] 10.1002/pbc.31381.
2024
Assessing Long-Term Neurologic Outcomes in SAMD9L-Related Ataxia-Pancytopenia Syndrome.
Movement disorders clinical practice.
11(6):728-733
[DOI] 10.1002/mdc3.14038.
[PMID] 38594844.
2024
Epstein Barr virus-directed T-cell therapy for refractory EBV-PTLD in a toddler post Orthotopic heart transplantation.
Pediatric transplantation.
28(2)
[DOI] 10.1111/petr.14707.
[PMID] 38419558.
2023
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial.
The Lancet. Haematology.
10(7):e510-e520
[DOI] 10.1016/S2352-3026(23)00088-1.
[PMID] 37407142.
2023
Feasibility study of busulfan, fludarabine, and thiotepa conditioning regimen for allogeneic hematopoietic stemcell transplantationfor children and young adults with nonmalignant disorders
Pediatric Blood & Cancer.
70(7)
[DOI] 10.1002/pbc.30322.
2023
Trends in Pediatric Cancer Care in Florida From 1981-2020: Changing Patterns in a Growing and Increasingly Diverse Population.
Cureus.
15(2)
[DOI] 10.7759/cureus.35061.
[PMID] 36938203.
2022
Establishing Cost-Effective Allocation of Proton Therapy for Patients With Mediastinal Hodgkin Lymphoma.
International journal of radiation oncology, biology, physics.
112(1):158-166
[DOI] 10.1016/j.ijrobp.2021.07.1711.
[PMID] 34348176.
2022
Volunteer-Based Social Support Structures and Program Exposure Outcomes in an Adolescent Young Adult Palliative Care Peer Support Program.
Journal of palliative medicine.
25(8):1186-1196
[DOI] 10.1089/jpm.2021.0426.
[PMID] 35333622.
2021
Eating behaviors and dietary quality in childhood acute lymphoblastic leukemia survivors
Pediatric Blood & Cancer.
68(4)
[DOI] 10.1002/pbc.28811.
2020
How we approach Philadelphia chromosome‐positive acute lymphoblastic leukemia in children and young adults
Pediatric Blood & Cancer.
67(10)
[DOI] 10.1002/pbc.28543.
2020
Incidence and Risk Factors for 30-Day Readmission after Inpatient Chemotherapy among Acute Lymphoblastic Leukemia Patients.
Healthcare (Basel, Switzerland).
8(4)
[DOI] 10.3390/healthcare8040401.
[PMID] 33066571.
2020
Irradiating Residual Disease to 30 Gy with Proton Therapy in Pediatric Mediastinal Hodgkin Lymphoma.
International journal of particle therapy.
6(4):11-16
[DOI] 10.14338/IJPT-19-00077.1.
[PMID] 32582815.
2020
Post Transplant Lymphoproliferative Disorder risk factors in children: Analysis of a 23-year single-institutional experience.
Pediatric transplantation.
24(5)
[DOI] 10.1111/petr.13747.
[PMID] 32497335.
2020
Primary pulmonary artery sarcoma in the pediatric patient: Review of literature and a case report.
Radiology case reports.
15(7):1110-1114
[DOI] 10.1016/j.radcr.2020.05.016.
[PMID] 32477441.
2019
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.
Blood advances.
3(12):1837-1847
[DOI] 10.1182/bloodadvances.2018028316.
[PMID] 31208955.
2019
Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15Rα Signaling.
Current gene therapy.
19(1):40-53
[DOI] 10.2174/1566523218666181116093857.
[PMID] 30444200.
2018
Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0622.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
36(22):2306-2314
[DOI] 10.1200/JCO.2017.76.7228.
[PMID] 29812996.
2017
Developmental Stage-Specific Manifestations of Absent TPO/c-MPL Signalling in Newborn Mice.
Thrombosis and haemostasis.
117(12):2322-2333
[DOI] 10.1160/TH17-06-0433.
[PMID] 29212120.
2017
Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma.
Advances in radiation oncology.
2(2):197-203
[DOI] 10.1016/j.adro.2017.01.006.
[PMID] 28740932.
2017
Minimal Change Disease as Initial Presentation of ALK-Positive Anaplastic Large-Cell Lymphoma in a Pediatric Patient.
Case reports in oncology.
10(3):964-972
[DOI] 10.1159/000481851.
[PMID] 29279700.
2017
Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients.
Experimental hematology & oncology.
6
[DOI] 10.1186/s40164-017-0087-0.
[PMID] 29021921.
2016
Proton Therapy for Pediatric Hodgkin Lymphoma.
Pediatric blood & cancer.
63(9):1522-6
[DOI] 10.1002/pbc.26044.
[PMID] 27149120.
2015
Generating Potent Chimeric Antigen Receptor T Cells Using Interleukin 15 Receptor Alpha Signal as a Co-Stimulatory Domain
Pediatric Blood & Cancer.
62(2)
2015
Near Fatal Presentation of Neuro-Degenerative Langerhans Cell Histiocytosis
Pediatric Blood & Cancer.
62(2)
2015
Proton therapy to the subdiaphragmatic region in the management of patients with Hodgkin lymphoma.
Leukemia & lymphoma.
56(7):2019-24
[DOI] 10.3109/10428194.2014.975802.
[PMID] 25315071.
2015
Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome.
Leukemia research reports.
4(1):24-7
[DOI] 10.1016/j.lrr.2015.03.002.
[PMID] 25893166.
2014
Bartonella henselae infection inducing hemophagocytic lymphohistiocytosis in a kidney transplant recipient.
Pediatric transplantation.
18(3):E83-7
[PMID] 24829973.
2014
Integrin VLA-5 and FAK are Good Targets to Improve Treatment Response in the Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.
Frontiers in oncology.
4
[DOI] 10.3389/fonc.2014.00112.
[PMID] 24860788.
2014
Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study.
International journal of radiation oncology, biology, physics.
89(5):1053-1059
[DOI] 10.1016/j.ijrobp.2014.04.029.
[PMID] 24928256.
2014
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL0031.
Leukemia.
28(7):1467-71
[DOI] 10.1038/leu.2014.30.
[PMID] 24441288.
2014
Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children’s Oncology Group Study AALL0031.
Leukemia.
28(4):964-7
[DOI] 10.1038/leu.2014.29.
[PMID] 24434862.
2013
Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans.
PloS one.
8(3)
[DOI] 10.1371/journal.pone.0059675.
[PMID] 23544085.
2013
Molecular mechanisms of platelet and stem cell rebound after 5-fluorouracil treatment.
Experimental hematology.
41(7):635-645.e3
[DOI] 10.1016/j.exphem.2013.03.003.
[PMID] 23507524.
2012
Characteristics of thawed autologous umbilical cord blood.
Transfusion.
52(10):2234-42
[DOI] 10.1111/j.1537-2995.2011.03556.x.
[PMID] 22321210.
2012
Continuous Dose Dasatinib Is Safe and Feasible in Combination With Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ All): Children’s Oncology Group (Cog) Trial Aall0622
Blood.
120
2012
Improving the therapeutic ratio in Hodgkin lymphoma through the use of proton therapy.
Oncology (Williston Park, N.Y.).
26(5):456-9, 462
[PMID] 22730602.
2012
Juvenile myelomonocytic leukemia in a 16-year-old with Noonan syndrome: case report.
Journal of pediatric hematology/oncology.
34(7):569-72
[PMID] 22510777.
2012
Outstanding Early Responses With Dasatinib and Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph Plus All): Children’s Oncology Group (Cog) Trial Aall0622
Pediatric Blood & Cancer.
59
2012
The Need for Gene Therapy for the Effective Treatment of Hemophilia.
Journal of genetic syndromes & gene therapy.
Suppl 1
[PMID] 25309817.
2010
Differences between newborn and adult mice in their response to immune thrombocytopenia.
Neonatology.
98(1):100-8
[DOI] 10.1159/000280413.
[PMID] 20134184.
2010
Intrinsic and extrinsic effects of mafG deficiency on hematopoietic recovery following bone marrow transplant.
Experimental hematology.
38(12):1251-60
[DOI] 10.1016/j.exphem.2010.08.005.
[PMID] 20813153.
2010
Neonatal Megakaryocytes Do Not Mature Normally in the Absence of Thrombopoietin in Vivo: Potential Role of Developmental Differences in Cxcr4 Expression
Blood.
116
2010
Post-transplant lymphoproliferative disorder in children: recent outcomes and response to dual rituximab/low-dose chemotherapy combination.
Pediatric transplantation.
14(7):896-902
[DOI] 10.1111/j.1399-3046.2010.01370.x.
[PMID] 20642490.
2010
Post-Transplant Lymphoproliferative Disorders in Children: Recent Outcomes and Response To Dual Rituximab/Chemotherapy Combination
American Journal of Transplantation.
10
2010
Screening Small Molecule Inhibitors of Vla-5 To Block the Interaction Between Acute Lymphoblastic Leukemia With Ph Plus and Their Microenvironment
Blood.
116
2009
Congenital cytopenias and bone marrow failure syndromes.
Seminars in perinatology.
33(1):20-8
[DOI] 10.1053/j.semperi.2008.10.009.
[PMID] 19167578.
2009
High levels of acetylated low-density lipoprotein uptake and low tyrosine kinase with immunoglobulin and epidermal growth factor homology domains-2 (Tie2) promoter activity distinguish sinusoids from other vessel types in murine bone marrow.
Circulation.
120(19):1910-8
[DOI] 10.1161/CIRCULATIONAHA.109.871574.
[PMID] 19858415.
2009
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
27(31):5175-81
[DOI] 10.1200/JCO.2008.21.2514.
[PMID] 19805687.
2009
MLL/AF-4 leukemic cells recruit new blood vessels but do not incorporate into capillaries in culture or in a NOD/SCID xenograft model.
Leukemia.
23(5):990-3
[DOI] 10.1038/leu.2008.345.
[PMID] 19158831.
2009
Post-Transplant Lymphoproliferative Disorder in Children: Recent Clinical Characteristics, Outcomes and Response To Dual Rituximab/Chemotherapy Combination
American Journal of Transplantation.
9
2009
Post-Transplant Lymphoproliferative Disorder in Children: Recent Clinical Characteristics, Outcomes and Response To Dual Rituximab/Chemotherapy Combination
American Journal of Transplantation.
9
2008
Bone marrow sinusoidal endothelial cells undergo nonapoptotic cell death and are replaced by proliferating sinusoidal cells in situ to maintain the vascular niche following lethal irradiation.
Experimental hematology.
36(9):1143-1156
[DOI] 10.1016/j.exphem.2008.06.009.
[PMID] 18718416.
2008
Optimization of recombinant adeno-associated viral vectors for human beta-globin gene transfer and transgene expression.
Human gene therapy.
19(4):365-75
[DOI] 10.1089/hum.2007.173.
[PMID] 18399730.
2008
Philadelphia Chromosome Negative (Ph-) Very High Risk (Vhr) Acute Lymphoblastic Leukemia (All) in Children and Adolescents: the Impact of Intensified Chemotherapy On Early Event Free Survival (Efs) in Children’S Oncology Group (Cog) Study Aall0031
Blood.
112:337-338
2008
Recombinant self-complementary adeno-associated virus serotype vector-mediated hematopoietic stem cell transduction and lineage-restricted, long-term transgene expression in a murine serial bone marrow transplantation model.
Human gene therapy.
19(4):376-83
[DOI] 10.1089/hum.2007.143.
[PMID] 18370591.
2008
Stable integration of recombinant adeno-associated virus vector genomes after transduction of murine hematopoietic stem cells.
Human gene therapy.
19(3):267-78
[DOI] 10.1089/hum.2007.161.
[PMID] 18303957.
2008
Type 2B von Willebrand disease associated with the release of platelet agglutinates from megakaryocytes in the bone marrow.
Journal of pediatric hematology/oncology.
30(9):708-11
[DOI] 10.1097/MPH.0b013e31817541cd.
[PMID] 18776767.
2007
Sites and kinetics of donor thrombopoiesis following transplantation of whole bone marrow and progenitor subsets.
Experimental hematology.
35(10):1567-79
[PMID] 17697746.
2007
The role of the donor in the repair of the marrow vascular niche following hematopoietic stem cell transplant.
Stem cells (Dayton, Ohio).
25(11):2945-55
[PMID] 17656638.
2007
Umbilical cord blood produces small megakaryocytes after transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
13(2):145-50
[PMID] 17241920.
2006
Differential effects of recombinant thrombopoietin and bone marrow stromal-conditioned media on neonatal versus adult megakaryocytes.
Blood.
108(10):3360-2
[PMID] 16888093.
2006
Evaluation of primitive murine hematopoietic stem and progenitor cell transduction in vitro and in vivo by recombinant adeno-associated virus vector serotypes 1 through 5.
Human gene therapy.
17(3):321-33
[PMID] 16544981.
2006
Stem cell research.
Paediatric respiratory reviews.
7(2):135-40
[PMID] 16765300.
2005
Developmental differences in megakaryocyte maturation are determined by the microenvironment.
Stem cells (Dayton, Ohio).
23(9):1400-8
[PMID] 16210411.
2004
A neonate with severe thrombocytopenia and radio-ulnar synostosis.
Journal of perinatology : official journal of the California Perinatal Association.
24(8):528-30
[PMID] 15282617.
2004
PU.1 supports proliferation of immature erythroid progenitors.
Leukemia research.
28(1):83-9
[PMID] 14630084.
2003
Characterization of thymic progenitors in adult mouse bone marrow.
Journal of immunology (Baltimore, Md. : 1950).
170(4):1877-86
[PMID] 12574354.
2003
Dapsone therapy for children with immune thrombocytopenic purpura.
Journal of pediatric hematology/oncology.
25(2):173-5
[PMID] 12571474.
2003
Early stages of hematopoietic differentiation.
Annals of the New York Academy of Sciences.
996:186-94
[PMID] 12799296.
2003
Response to intravenous immunoglobulin predicts splenectomy response in children with immune thrombocytopenic purpura.
Pediatrics.
111(1):87-90
[PMID] 12509559.
2002
High incidence of epithelial cancers in mice deficient for DNA polymerase delta proofreading.
Proceedings of the National Academy of Sciences of the United States of America.
99(24):15560-5
[PMID] 12429860.
2002
Lineage-specific trisomy 21 in a neonate with resolving transient myeloproliferative syndrome.
Journal of pediatric hematology/oncology.
24(3):224-6
[PMID] 11990311.
2002
The spleen is a major site of megakaryopoiesis following transplantation of murine hematopoietic stem cells.
Blood.
100(12):3975-82
[PMID] 12393568.
2002
Using fluorescence-activated cell sorting followed by fluorescence in situ hybridization to study lineage relationships: the 8;21 translocation is present in neutrophils but not monocytes in a patient with severe congenital neutropenia and a granulocyte colony-stimulating factor-responsive clonal abnormality.
Acta paediatrica (Oslo, Norway : 1992). Supplement.
91(438):120-3
[PMID] 12477275.
2001
Observations of residual differentiation potential during lineage commitment.
Annals of the New York Academy of Sciences.
938:157-65; discussion 165
[PMID] 11458503.
2001
Phenotypic distinction and functional characterization of pro-B cells in adult mouse bone marrow.
Journal of immunology (Baltimore, Md. : 1950).
166(5):3042-51
[PMID] 11207254.
2000
Congenital bone marrow failure syndromes associated with protean developmental defects and leukemia.
Clinics in perinatology.
27(3):543-58
[PMID] 10986628.
2000
Rapid, B lymphoid-restricted engraftment mediated by a primitive bone marrow subpopulation.
Journal of immunology (Baltimore, Md. : 1950).
165(1):67-74
[PMID] 10861036.
1998
Hematopoiesis in the liver and marrow of human fetuses at 5 to 16 weeks postconception: quantitative assessment of macrophage and neutrophil populations.
Pediatric research.
43(6):774-82
[PMID] 9621987.
1998
The first-appearance of neutrophils in the human fetal bone marrow cavity.
Early human development.
53(2):129-44
[PMID] 10195706.
1997
Use of alternative therapies for children with cancer.
Pediatrics.
100(6)
[PMID] 9382902.
1996
Tetany in a child with AIDS receiving intravenous tobramycin.
Southern medical journal.
89(11):1108-10
[PMID] 8903300.
1995
Testosterone induced priapism in two adolescents with sickle cell disease.
Journal of pediatric endocrinology & metabolism : JPEM.
8(3):199-203
[PMID] 8521195.
1983
The immunological response of Wistar rats to the intracranially implanted C-6 glioma cell line.
Journal of neuro-oncology.
1(4):365-72
[PMID] 6678975.
Grants
Jul 2023
ACTIVE
CMS Hematology/Oncology – COQXE Renewal FY24-26
Role: Principal Investigator
Funding: FL DEPT OF HLTH CHILDRENS MED SERVS
via US DEPT OF HLTH & HUMAN SER OFFICE OF RE
May 2023
ACTIVE
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
May 2023
ACTIVE
Phase 2 Study of DAY101 in Relapsed and Refractory Langerhans Cell Histiocytosis
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Apr 2023
ACTIVE
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Role: Project Manager
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Apr 2023
ACTIVE
2022 Amazon High-Impact Initiative
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via AMAZON.COM
Mar 2023
ACTIVE
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Jan 2023
ACTIVE
A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Jan 2023
– Dec 2023
Reducing the Burden of Oncologic Chemoradiotherapy And Radiation Exposure from Diagnostic Imaging by Utilizing Targeted Immunotherapy in Children, Adolescents and Young Adults with Lymphoma (RADICAL)
Role: Principal Investigator
Funding: NEW YORK MEDICAL COLLEGE
via PEDIATRIC CANCER RESEARCH FOU
Oct 2022
ACTIVE
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
Role: Project Manager
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Jul 2022
ACTIVE
A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Jul 2022
ACTIVE
Comparing Functional and Quality of Life Outcomes after Selumetinib vs.
Carboplatin/Vincristine in Children with Newly Diagnosed Low-Grade Glioma
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via PEDIATRIC BRAIN TUMOR FOUNDATION
Jun 2022
– Jun 2023
Study of Sickle Cell Disease
Role: Principal Investigator
Funding: FLORIDA MEDICAL SCHOOLS QUALITY NETWORK
via AGCY FOR HLTH CARE ADMN
May 2022
– Jul 2024
Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
May 2022
ACTIVE
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Apr 2022
ACTIVE
Pediatric Acute Leukemia (PedAL) Screening Trial Developing New Therapies for Relapsed Leukemias
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Apr 2022
ACTIVE
A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via PFIZER INC
Apr 2022
ACTIVE
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via PFIZER INC PHARMACEUTICALS
Mar 2022
ACTIVE
Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via LEUKEMIA & LYMPHOMA SOC
Mar 2022
– Oct 2023
Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via LEUKEMIA & LYMPHOMA SOC
Mar 2022
ACTIVE
Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via AMGEN INC
Mar 2022
ACTIVE
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via JAZZ PHARMACEUTICALS
Mar 2022
– Oct 2023
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via JAZZ PHARMACEUTICALS
Feb 2022
ACTIVE
Phase 1 Study to Evaluate Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide and/or In Combination with Topotecan and Cyclophosphamide in Pediatric Patients with Recurrent or Refractory Solid Tumors
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via PFIZER INC
Jan 2022
– Oct 2023
A Safety, Pharmacokinetic and Efficacy Study of a ?-Secretase Inhibitor, Nirogacestat (PF 03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via SPRINGWORKS THERAPEUTICS
Nov 2021
ACTIVE
A Randomized Phase 3 trial of Nivolumab(NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Nov 2021
ACTIVE
A Phase III Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/=12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Nov 2021
ACTIVE
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia – Chronic Phase (CML-CP)
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Oct 2021
ACTIVE
ARST2031: A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Mai
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Jul 2021
ACTIVE
A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors ALTE2031
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Jul 2021
ACTIVE
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
May 2021
ACTIVE
A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Mar 2021
ACTIVE
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Mar 2021
ACTIVE
A Phase III Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/=12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Mar 2021
ACTIVE
COG Chair Grant
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Mar 2021
– Jun 2024
A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Jan 2021
– Jul 2023
ACCL1633, The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Dec 2020
ACTIVE
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >1 to < 31 Years Old With First Relapse
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Dec 2020
ACTIVE
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Nov 2020
ACTIVE
A Safety, Pharmacokinetic and Efficacy Study of a ?-Secretase Inhibitor, Nirogacestat (PF 03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Oct 2020
ACTIVE
An Open Label Feasibility Study to Assess the Safety and
Pharmacokietics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) with an Isocitrate Dehydrogenase-2 (IDH2) Mutation
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via CELGENE CORP
Oct 2020
ACTIVE
NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF AG-120 (IVOSIDENIB) IN PATIENTS WITH TUMORS HARBORING IDH1 MUTATIONS
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Sep 2020
– Oct 2023
A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF 03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via DESMOID TUMOR RESEARCH FOU
Sep 2020
– Nov 2024
NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF LOXO-292 IN PATIENTS WITH TUMORS HARBORING RET GENE ALTERATIONS
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Aug 2020
– Oct 2023
A Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via EISAI
Aug 2020
– Jul 2021
AALL1131 Supplemental PCR
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Jul 2020
ACTIVE
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Jul 2020
ACTIVE
NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF TIPIFARNIB IN PATIENTS WITH TUMORS HARBORING HRAS GENOMIC ALTERATIONS
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Jul 2020
ACTIVE
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, And Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed By High-Dose Carboplatin And Etoposide (TI-CE) As Firs
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Jun 2020
ACTIVE
A Phase I/II Study of Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph+ Chronic Myeloid Leukemia
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via PFIZER INC
Jun 2020
– Jun 2024
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via ASTRAZENECA UK
May 2020
– Feb 2021
A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC#681239, NSC#724772) for Patients with High Allelic Ration FLT3/ITD
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Mar 2020
– Jul 2022
AN OPEN-LABEL FEASIBILITY STUDY TO ASSESS THE SAFETY AND PHARMACOKINETICS OF ENASIDENIB IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R-AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Mar 2020
– Oct 2022
Larotrectinib For Previously Untreated NTRK-fusion Positive Pediatric Solid Tumors and NTRK-fusion Positive Relapsed Pediatric Acute Leukemias
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via BAYER AG
Mar 2020
– Feb 2021
Specimen Banking Supplements
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Jan 2020
ACTIVE
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Oct 2019
ACTIVE
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (NCORP funding)
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Oct 2019
ACTIVE
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (NCTN funding)
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Oct 2019
– Jul 2022
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Oct 2019
– Oct 2024
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Oct 2019
– Sep 2020
Dolls, Books, Pill crushers, and thermometers
Role: Principal Investigator
Funding: UF MEDICAL GUILD
Aug 2019
– Jul 2023
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via MERCK SHARP & DOHME
Aug 2019
ACTIVE
A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphobl
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Jul 2019
– Jun 2023
FLDOH CMS Hematology/Oncology – COQXE A4
Role: Principal Investigator
Funding: FL DEPT OF HLTH CHILDRENS MED SERVS
via US DEPT OF HLTH & HUMAN SER OFFICE OF RE
May 2019
ACTIVE
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
May 2019
ACTIVE
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
May 2019
ACTIVE
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PT
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
May 2019
ACTIVE
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
May 2019
ACTIVE
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
May 2019
ACTIVE
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
May 2019
ACTIVE
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
May 2019
ACTIVE
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Ulixertinib in patients with tumors harboring activating MAPK pathway mutations
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
May 2019
ACTIVE
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
May 2019
ACTIVE
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
May 2019
ACTIVE
Phase 2 Trial of Cabozantinib (XL184), an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Nephroblastoma (Wilms Tumor), and Other Rare Tumors
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
May 2019
ACTIVE
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
May 2019
– Oct 2024
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
May 2019
– Apr 2022
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
May 2019
– Aug 2021
Work Order to the Master Subaward Agreement for Non-Industry Funding Sources between The Children's Hospital of Philadelphia Contracting on behalf of the Children's Oncology Group ("CHOP") and University of Florida ("Subcontractee")
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
May 2019
– Feb 2021
NIH COG Chair Grant
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Mar 2019
ACTIVE
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Mar 2019
ACTIVE
ARST1431, A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rh
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Mar 2019
ACTIVE
Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Mar 2019
ACTIVE
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Mar 2019
ACTIVE
Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Mar 2019
ACTIVE
The Effectiveness of Lactobacillus Plantarum (LBP) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Feb 2019
– Feb 2024
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via *JUBILANT DRAXIMAGE
Feb 2019
– Feb 2024
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via PFIZER INC
Nov 2018
– Mar 2022
A Phase I Trial of Pevonedistat in Combination With Induction Chemotherapy for Adolescent and Young Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia
Role: Principal Investigator
Funding: UNIV OF MIAMI
via MILLENNIUM PHARMACEUTICAL
Oct 2018
– Feb 2019
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Oct 2018
– Jan 2023
A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Venous Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (T or B cell) Treated with Asparaginase
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via BRISTOL MYERS SQUIBB CO
Oct 2018
– Feb 2019
NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)- PHASE 2 SUBPROTOCOL OF BVD-523FB (ULIXERTINIB) IN PATIENTS WITH TUMORS HARBORING ACTIVATING MAPK PATHWAY MUTATIONS
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Jul 2018
– Feb 2019
Phase 3 Accelerated BEP Trial: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Jun 2018
– Feb 2019
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Jun 2018
– Feb 2019
The Effectiveness of Lactobacillus Plantarum (LBP) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
May 2018
– Dec 2021
Intensified Methotrexate, Nelarbine (Compound 506U78;NCI IND #52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NOVARTIS US
May 2018
– May 2023
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
May 2018
– Dec 2021
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Standard Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Jan 2018
– Jan 2023
Phase 2 Study of Denosumab (IND#127430, NCS#744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Jan 2018
– Feb 2019
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Jan 2018
– Mar 2022
Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Nov 2017
– Nov 2022
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR 1/2/3/4 Alterations
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Oct 2017
– Feb 2019
Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Oct 2017
– Feb 2019
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Aug 2017
– Aug 2022
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Aug 2017
– Aug 2022
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Aug 2017
– Aug 2022
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via ST BALDRICKS FOUNDATION
Aug 2017
– Feb 2019
NCI-COG Pediatric Molecular Analysis for Therapy Choice MATCH – Phase 2 Subprotocol of LY3023414 in Solid Tumors
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Jul 2017
– Feb 2019
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Jul 2017
– Jul 2022
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Jul 2017
– Jul 2022
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Jul 2017
– Jul 2022
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Jul 2017
– Jul 2022
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring Braf V600 Mutations
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Jul 2017
– Feb 2019
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Jul 2017
– Feb 2019
NCI-COG Pediatric Molecular Analysis for Therapy Choice MATCH – Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Jul 2017
– Jun 2023
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via CHILDRENS ONCOLOGY GROUP
Jun 2017
– Jun 2022
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
May 2017
– Feb 2019
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
May 2017
– Feb 2019
Phase 2 Trial of Cabozantinib (XL184), an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Mar 2017
– Mar 2022
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Mar 2017
– Feb 2019
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Oct 2016
– Sep 2017
Thermometers, Pill crushers, and Pill Splitters for Pediatrics Hematology Oncology Patients.
Role: Principal Investigator
Funding: UF MEDICAL GUILD
Aug 2016
– Jun 2022
A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD.
Role: Principal Investigator
Funding: BAYER PHARMACEUTICALS CORP
via CHILDRENS ONCOLOGY GROUP
Aug 2016
– Aug 2021
A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Jul 2016
– May 2023
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Role: Principal Investigator
Funding: PUBLIC HLTH INST
Jul 2016
ACTIVE
CMS Newborn Screening – COQWX
Role: Principal Investigator
Funding: FL DEPT OF HLTH CHILDRENS MED SERVS
May 2016
– Feb 2019
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosar
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Apr 2016
– Feb 2019
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Apr 2016
– Feb 2019
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Dec 2015
– Dec 2018
AN INTERMEDIATE SIZE EXPANDED ACCESS PROTOCOL BRINCIDOFOVIR FOR THE TREATMENT OF SERIOUS ADENOVIRUS INFECTION OR DISEASE
Role: Principal Investigator
Funding: Chimerix, Inc.
Nov 2015
– Feb 2019
A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Nov 2015
– Feb 2019
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Oct 2015
ACTIVE
The Project:EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
Jul 2015
– Jun 2020
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, And Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed By High-Dose Carboplatin And Etoposide (TI-CE) As Firs
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Apr 2015
– Apr 2020
Work order -NCORP
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Dec 2014
– Feb 2019
Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
via NATL INST OF HLTH NCI
Oct 2014
– May 2018
Community Central Line Infection Prevention (CCLIP) Trial
Role: Principal Investigator
Funding: JOHNS HOPKINS UNIVERSITY
via AGENCY FOR HEALTHCARE RES AND QUALITY
Apr 2014
– Apr 2017
INTERGROUP TRIAL FOR CHILDREN OR ADOLESCENTS WITH B-CELL NHL OR B-AL: EVALUATION OF RITUXIMAB EFFICACY AND SAFETY IN HIGH RISK PATIENTS
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via HOFFMANN LA ROCHE
Apr 2014
– Apr 2022
Larotrectinib (LOXO-101, NSC# 788607, IND#141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Apr 2014
– Feb 2019
NIH COG Chair Grant
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Apr 2014
– Feb 2019
Work Order To The Master Subaward Agreement For Non-Industry Funding Sources Between The Children's Hospital of Philadelphia Contracting On Behalf of the Children's Oncology Group ("CHOP") And University of Florida ("Subcontractee")
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via NATL INST OF HLTH NCI
Jan 2014
– May 2020
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
Jul 2013
– Dec 2019
Re-MATCH: Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive Cell Therapy During Recovery from Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation
Role: Project Manager
Funding: US ARMY MED RES ACQUISITION
Jan 2013
– Jan 2020
A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD.
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP
Nov 2012
– Nov 2018
Phase IB Study of the Safety, Tolerance, and Phrmacokinetics of Oral posaconazole in Immunocompromised Children with Neutropenia.
Role: Principal Investigator
Funding: Merck Sharp & Dohme
Oct 2012
– Oct 2020
Stop Children's Cancer Professorship
Role: Principal Investigator
Funding: UF FOUNDATION
May 2012
– May 2022
SLAYTON – 214 CLINICAL TRIAL ADMINISTRATION SUPPORT
Role: Principal Investigator
Funding: 214 OPERATING ACCOUNT
Apr 2012
– Feb 2022
CHOP Work Order – ST. BALDRICKS FOUNDATION SUPPLEMENTAL REIMBURSEMENT
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
via ST BALDRICKS FOUNDATION
Apr 2012
– Jul 2016
COG Grant: Non-industry Funds per case reimbursement: abstract of Children's Oncology Group Program
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA
Feb 2011
– Jan 2016
A Phase I Window, Dose Escalating and Safety Trial of Metformin in Combination with Induction Chemotherapy in Relapsed Refractory Acute Lymphoblastic Leukemia: Metformin with Induction Chemotherapy of Vincris
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR & RES INST
Oct 2010
– Jun 2016
CMS Hematology/Oncology Program
Role: Principal Investigator
Funding: FL DEPT OF HLTH CHILDRENS MED SERVS
Aug 2010
– Aug 2016
A Phase II Trial of External Beam Radiation Therapy and Cetuximab followed by Irinotecan and Cetuximab for Children and Young Adults with Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
Role: Principal Investigator
Funding: THE CHILDRENS HOSPITAL ASSO
via BRISTOL MYERS SQUIBB CO
Jul 2010
– May 2017
A Phase II Study of RAD001 (Everolimus) for Children with Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas
Role: Principal Investigator
Funding: DANA FARBER CANCER INST
Jul 1996
– Jun 2022
04052939
Role: Principal Investigator
Funding: UF RESEARCH FOU
via MULTIPLE SPONSORS
May 1990
– Jun 2017
90090416 SHANDS TEACHING HOSPITAL TELETHON AWARD PROGRAM
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Education
Fellowship – Pediatric Hematology/Oncology
1996
·
University of Florida
Internship – Pediatrics
1993
·
University of Florida
Residency – Pediatrics
1993
·
University of Florida
Medical Degree
1992
·
University of Florida
Bachelor of Arts in Biology
1985
·
Oberlin College
Contact Details
Phones:
- Business:
- (352) 273-9120
Emails:
- Business:
- wslayton@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100296
GAINESVILLE FL 32610 - Business Street:
-
PO Box 100296
GAINESVILLE FL 32610